Biosimilar Makers Join Forces To Fight Takeda Entyvio IP
Four biosimilar drugmakers have asked a London judge to revoke a slew of Takeda patents covering its blockbuster drug for inflammatory bowel ailments such as Crohn's disease, arguing that its dosage...To view the full article, register now.
Already a subscriber? Click here to view full article